As the US House of Representatives' influential Oversight and Accountability Committee chairman James Comer (R-KY) prepares for a markup of legislation aimed at decoupling the biopharma industry from Chinese manufacturers and developers, he is also pressing the US Food and Drug Administration on a separate track.
In a 6 May letter to FDA, Comer warned the committee sees it as “increasingly clear that the CCP [Chinese...






